Care Management for Rare and Orphan Diseases

Rare and orphan diseases present a structurally distinct challenge for care management: low patient volume, dispersed clinical expertise, limited evidence-based treatment protocols, and payer policies that were not designed for conditions affecting fewer than 200,000 individuals in the United States. This page defines the scope of care management as it applies to rare and orphan disease populations, describes the operational framework used by care teams, identifies common clinical and administrative scenarios, and outlines the boundaries that separate standard care management from specialized rare-disease coordination. Understanding these distinctions matters for payers, health systems, case managers, and patient advocacy organizations navigating a regulatory landscape that spans the FDA Office of Orphan Products Development, CMS reimbursement structures, and standards set by the Commission on Case Manager Certification (CCMC).

Definition and Scope

The U.S. Food and Drug Administration defines a rare disease as one affecting fewer than 200,000 persons in the United States, a threshold established by the Orphan Drug Act of 1983 and codified at 21 U.S.C. § 360bb. Approximately 7,000 distinct rare diseases have been identified globally, according to the National Institutes of Health National Center for Advancing Translational Sciences (NCATS), and roughly 80 percent have a genetic origin.

Care management for rare and orphan diseases encompasses the full continuum of assessment, planning, facilitation, care coordination, evaluation, and advocacy functions described in the CCMC's definition of case management — but applied within structural constraints that differ substantially from those governing chronic disease care management or population health management. Key scope characteristics include:

• Patient rarity: Prevalence so low that individual health plans may cover only 1–20 affected members at any time, making actuarial risk modeling and utilization benchmarking unreliable.
• Diagnostic delay: NIH data indicates an average diagnostic delay of 4 to 8 years for rare disease patients before confirmed diagnosis, creating a gap during which care management cannot be formally initiated under a confirmed diagnostic code.
• Geographic dispersion: Recognized centers of excellence and specialist networks (often designated through NIH Rare Diseases Clinical Research Network programs) are concentrated in academic medical centers, requiring out-of-network navigation by care managers.
• Orphan drug complexity: More than 600 orphan-designated drugs have received FDA approval since 1983 (FDA Office of Orphan Products Development), many requiring specialty pharmacy routing, prior authorization, and risk evaluation and mitigation strategies (REMS programs) that fall within the utilization management workflow.

The distinction between a rare disease and an orphan disease is regulatory, not clinical. An orphan disease qualifies for designation specifically to incentivize drug development; a rare disease is an epidemiological category. All orphan diseases meeting the U.S. prevalence threshold are rare diseases, but a disease may be rare without having received orphan drug designation.

How It Works

Care management for rare and orphan disease populations follows a phased framework consistent with CCMC Case Management Standards of Practice but adapted at each phase for the disease-specific context.

• Identification and referral: Members are flagged through diagnostic codes, specialty pharmacy claims, high-cost claimant reports, or physician referral. ICD-10-CM includes dedicated codes for rare and hereditary conditions, enabling automated identification within health plan systems. Many rare conditions appear under Chapter 17 (Congenital malformations) or Chapter 21 (Factors influencing health status) of ICD-10-CM (CDC ICD-10-CM Browser).
• Comprehensive assessment: A biopsychosocial assessment is conducted covering medical complexity, functional status, caregiver burden, insurance coverage gaps, social determinants of health, and patient literacy regarding their condition. For rare diseases, this assessment must also document current treatment access, active clinical trial eligibility, and out-of-network specialist relationships.
• Care plan development: The patient-centered care plan for a rare disease patient specifies goals that account for disease progression modeling (often based on natural history studies rather than randomized controlled trials), specialist visit cadence, laboratory monitoring schedules, and emergency protocol documentation. Plans must address both the treating specialist and the primary care physician's roles.
• Care coordination across settings: The care manager coordinates among qualified professionals center, primary care, specialty pharmacy, durable medical equipment suppliers, and genetic counselors. This interdisciplinary model aligns with standards described by the interdisciplinary care teams framework and may include liaison with disease-specific patient registries or foundation-operated nurse navigator programs.
• Authorization and appeals management: Prior authorizations for orphan drugs frequently trigger medical necessity reviews. Care managers familiar with the FDA's orphan drug approval pathway and the relevant CMS coverage determination framework (CMS National Coverage Determinations) are better positioned to prepare or support clinical documentation for appeals.
• Ongoing monitoring and reassessment: Rare disease trajectories change with treatment response. Reassessment intervals are typically shorter — often every 30 to 60 days for newly initiated orphan drug therapy — compared to 90 to 180 day cycles common in standard chronic disease programs.
• Transition planning: When patients transition between pediatric and adult care systems, or between acute and post-acute settings, dedicated transitional care management protocols are applied. Pediatric rare disease patients transitioning to adult care represent a particularly high-risk juncture, as adult specialists with disease-specific expertise may not be available within a network.

Common Scenarios

Rare disease care management presents several recurring operational patterns that distinguish it from standard high-complexity case management.

Scenario A — Lysosomal Storage Disorder on Enzyme Replacement Therapy (ERT) A patient with Gaucher disease type 1 receives biweekly intravenous enzyme replacement therapy at a licensed infusion center. The care manager coordinates infusion scheduling, monitors for infusion-related adverse events, tracks hematologic laboratory values, and facilitates communication between the hematologist and the specialty pharmacy dispensing imiglucerase. Authorization renewal occurs on a 6-month cycle and requires updated clinical documentation confirming therapeutic response per the treating specialist's criteria.

Scenario B — Undiagnosed Rare Disease Pending Genetic Workup A patient with a multi-system presentation has received no confirmed rare disease diagnosis after 3 years of evaluation. The care manager operates without a confirming diagnostic code, relying on symptom-based ICD codes. Coordination targets include facilitating referral to an NIH Undiagnosed Diseases Network (UDN) site, managing authorization for whole exome sequencing, and maintaining communication between 4 separate subspecialists across 2 health systems.

Scenario C — Pediatric Rare Disease with Caregiver Burnout A child with spinal muscular atrophy (SMA) type 2 receives gene therapy follow-up and ongoing physical therapy. The care manager identifies caregiver burnout through a validated screening instrument (e.g., Zarit Burden Interview) and coordinates access to respite care resources, Medicaid waiver programs, and support from the Cure SMA patient advocacy network. This scenario overlaps with pediatric care management and behavioral health care management functions.

Scenario D — Orphan Drug Prior Authorization Denial and Appeal A patient with pulmonary arterial hypertension is denied coverage for a recently approved prostacyclin pathway agent. The care manager compiles the treating cardiologist's clinical notes, the FDA prescribing label citing the orphan indication, and research-based natural history data to support the appeal. The process follows the internal appeal and external review procedures defined under the Affordable Care Act's external review standards and state-level independent review organization requirements.

Decision Boundaries

Rare disease care management occupies a defined operational space distinct from adjacent functions. The following boundaries clarify when and how it applies.

Rare Disease Care Management vs. Complex Care Management Complex care management addresses patients with high utilization driven by multi-morbidity, often without a single unifying diagnosis. Rare disease care management addresses a discrete diagnostic entity with specific therapeutic protocols, specialist networks, and regulatory dimensions (orphan drug status, REMS). A patient may qualify for both simultaneously, but the rare disease program typically drives care plan structure.

Rare Disease Care Management vs. Oncology Care Management Some oncologic conditions — such as specific pediatric cancers — carry orphan drug designations and low prevalence. Oncology care management follows tumor-board-driven protocols and oncology-specific reimbursement models (e.g., CMS Oncology Care Model). When a cancer carries an orphan designation, care management programs should align orphan drug access processes with oncology navigation workflows rather than treating them as parallel tracks.

Scope of Care Manager Function Care managers in rare disease programs do not determine medical necessity as clinical adjudicators — that function rests with the health plan's medical director under criteria such as those published by MCG Health or Milliman Care Guidelines. Care managers facilitate, coordinate, document, and communicate. The boundary between coordination and clinical decision-making is a compliance and liability boundary governed by state nurse practice acts and the CCMC's Code of Professional Conduct.

Reimbursement Eligibility Boundaries CMS Chronic Care Management (CCM) codes (CP

References

• Orphan Drug Act of 1983
• National Institutes of Health National Center for Advancing Translational Sciences (NCATS)
• FDA Office of Orphan Products Development
• CDC ICD-10-CM Browser
• CMS National Coverage Determinations
• UDN
• Affordable Care Act's